Transcription
Rabbie Kriakoss Hanna, MD 1Curriculum VitaePersonal Information:Rabbie Kriakoss Hanna, MDBirth date: March/1975Updated Aug/2020Cell: 248-464-7852Email: rabbie.hanna@mac.comAppointments:1. Oct 2015- Present: Wayne State University-Detroit/MichiganClinical Assistant Professor in Obstetrics andGynecology.2. Aug 2014- Aug 2020: Gynecologic Oncology AttendingGenesys Health System-Grand Blanc/Michigan.3. July 2011- Aug 2020: Gynecologic Oncology Senior StaffDivision of Gynecologic OncologyDepartment of Women’s HealthHenry Ford Health SystemDetroit, Michigan.4. Aug 2014- Jun 2017: Gynecologic Oncology AttendingHurley Medical Center-Flint/Michigan.Board Certifications and Licensure:1. Gynecologic Oncology/Board Certified April, 9th 2014.2. American College of Obstetricians and Gynecologists Jan, 2010.3. Restricted Training License, State of North Carolina 07/01/20083/29/2012.4. Michigan Physician License issued by the Board of Medicine at the Stateof Michigan: Initial issue date: 7/18/2007 (Current expiration 7/18/2023).5. Michigan State Controlled Substance License issued by the Board ofMedicine at the State of Michigan: Initial issue date: 7/1/2007 (Currentexpiration 7/18/2023).6. Drug Enforcement Administration (DEA) License (9/18/2019-10/31/2022).Education:1. August 2010: American Association for Cancer Research-AmericanSociety of Clinical Oncology (AACR-ASCO) Methods in Clinical CancerResearch Workshop. Protocol title: A Phase II Randomized Trial ofMetformin in Combination with Paclitaxel and Carboplatin vs. Paclitaxeland Carboplatin in the Treatment of Recurrent Endometrioid EndometrialCancer.2. 07/2008- 06/2011: Gynecologic Oncology fellowship training at TheUniversity of North Carolina at Chapel Hill.3. January 2007: Felix Rutledge fellowship in Gynecologic OncologyMD Anderson Cancer Center Houston, Texas.
Rabbie Kriakoss Hanna, MD 2Curriculum Vitae4. December 2006: Galloway fellowship in Gynecologic Oncology MemorialSloan-Kettering Cancer Center, New York, NY.5. 07/2004-06/2008: Obstetrics & Gynecology Residency, Wayne StateUniversity/Detroit Medical Center, Detroit, Michigan.6. Oct/1999-Aug-2000: Transitional Post-Graduate training, The UniversityTeaching Hospital of Al-Nahrain College of Medicine, Baghdad/IRAQ.7. Sep/1993 to June/1999: Premedical Sciences and Medical Doctor degreefrom Al-Nahrain College of Medicine (The former Saddam College ofMedicine) Baghdad/IRAQ.Honors and Awards:1. Dec 2018: An Award of Appreciation from the “High Institute of InfertilityDiagnosis and Assisted Reproductive Technologies” Al-Nahrain College ofMedicine, Baghdad/Iraq as a speaker regarding “Oncofertility”.2. Dec 2018: An Award of Appreciation from Al-Nahrain College of Medicine,Baghdad/Iraq as a speaker to the medical students, residents and faculty.3. Oct 2018 “Excellence in Teaching Award” awarded for excellence inmedical students 2017-18 teaching at Wayne State School of Medicine,Detroit, Michigan.4. June 2017 Obstetrics and Gynecology Faculty Award from GenesysHealth System Residents.5. Sep 2016: An Award of Appreciation from IRAQ as a speaker in TheSecond Multi-Disciplinary Oncology Course (MDOC) Iraq series:Gynecologic Oncology held in Sulaimanyiah/Iraq Sep 1-2/2016.6. June 2016: The “Clark P. Kirman Award” presented by the Henry FordHospital/Wayne State University Obstetrics and Gynecology Residents,Detroit, Michigan in recognition for surgical education.7. Dec 2015. Nominated for membership into the Gold Humanism HonorSociety.8. June 2012: The “Outstanding Teaching Award” presented by the HenryFord Hospital/Wayne State University Obstetrics and GynecologyResidents, Detroit, Michigan.9. March 2012: The “Society of Gynecologic Oncology Community LeaderExcellence Award” presented during the SGO awards session at the 43rdAnnual Meeting for Society of Gynecologic Oncology, Austin/Texas.10. June 2011: The "Fellows Award for Teaching Excellence" presented bythe University of North Carolina Obstetrics and Gynecology residents,Chapel Hill, North Carolina.11. June 2011: The “Golden Tar Heel Teaching Award” awarded forexcellence in medical students teaching at the University of North CarolinaSchool of Medicine, Chapel Hill, North Carolina.
Rabbie Kriakoss Hanna, MD 3Curriculum Vitae12. May 2010: Charles B Hammond Research Day Best Resident Researchat Duke University’s Obstetrics and Gynecology Residency Program for“Robin A. Laskey, Micael A. Lopez, Angeles Alvarez Secord, Marek S.Poniewierski, Paola A. Gehrig, Rabbie Hanna, Gary H. Lyman, Laura J.Havrilesky. Predictors of neutropenic events in women with advancedstage ovarian cancer treated with multi-agent intravenous chemotherapy”,presented as an oral presentation.13. October 2009: Mid-Atlantic Gynecologic Oncology Association 2009Fellow’s Award for “Hanna RK, Malloy KM, Zhou C, Gehrig, PA and BaeJump VL. Genistein and soy extract inhibit proliferation of endometrialcancer cells by G2 cell cycle arrest.” presented as an oral presentation.14. June 2008: The “Teshima Award” for Excellence in Gynecologic andGynecologic Oncology Care, 2007-2008 (From Wayne State Universityand Hutzel Women’s Hospital) Detroit, Michigan.15. June 2008: The “Angela Y. Dourron, M.D. Award” for Excellence inCompassionate Patient Care 2007-2008 (From Wayne State Universityand Hutzel Women’s Hospital) Detroit, Michigan.16. June 2008: The “Sidney F. Bottoms, M.D. Award” for Excellence inresearch “1st Place” (From Wayne State University and Hutzel Women’sHospital) Detroit, Michigan.17. January 2008 & Apr 2005 Outstanding Resident Efforts Award on Laborand Delivery at Hutzel Women’s Hospital, Detroit, Michigan.18. June 2006: The “Berlex Best Teaching Resident” Award for beingnominated as the Best PGY-2 Teaching Resident at Wayne StateUniversity, Obstetrics and Gynecology (among 11 residents) Detroit,Michigan.19. June 2005: The “Joan Stryker, M.D. Award” for Excellence inUndergraduate Teaching, 2004-2005 (From Wayne State University andHutzel Women’s Hospital) (among 11 residents) Detroit, Michigan.20. 1999-2000 Appreciation and gratitude awards while working as a houseofficer in the University Teaching Hospital, Al-Kadhymia-Baghdad/Iraq.Peer reviewed articles:1. Elshaikh MA, Modh A, Sakr S, Shrestha R, Burmeister C, Ali-FehmiR, Hanna RK.A Simplified Risk Stratification Method for Women WithStage I Endometrial Carcinoma. Am J Clin Oncol. 2019 Feb;42(2):131137. PMID: 30260801.2. Modh A, Ghanem AI, Burmeister C, Hanna RK, Elshaikh MA. What isthe Optimal Adjuvant Treatment Sequence for Node-PositiveEndometrial Cancer? Results of a National Cancer Database Analysis. IntJ Gynecol Cancer. 2018 Feb;28(2):248-253. PMID: 29240603.
Rabbie Kriakoss Hanna, MD 4Curriculum Vitae3. Lee JK, Mahan M, Hanna RK, Elshaikh MA. Survival Outcomes andPatterns of Failure in Women with Stage IIIC2 Endometrial Carcinoma.Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:192-197.4. Albuquerque K, Folkert M, Mayadev J, Christie A, Liotta MR, Nagel C,Sevak P, Harkenrider MM, Lea JS, Hanna RK, Small WC Jr, Miller DS,Xie XJ, Potkul RK, Elshaikh MA. Adjuvant External Radiation ImpactsOutcome of Pelvis-limited Stage III Endometrial Carcinoma: A Multiinstitutional Study. Am J Clin Oncol. 2018 Aug;41(8):792-796. PMID:28225446.5. Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK,Method M, Ade M, Ivanova A, Boggess JF. A comparison of sentinellymph node biopsy to lymphadenectomy for endometrial cancer staging(FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017Mar;18(3):384-392.6. Khalife T, Hanna RK. The K-Technique: A Novel Technique forLaparoscopic Apical Suspension Using Barbed Sutures. Female PelvicMed Reconstr Surg. 2017 Mar/Apr;23(2):157-161.7. Isrow D, Burmeister C, Hanna RK, Elshaikh MA. Survival endpoints foryoung women with early stage uterine endometrioid carcinoma: a matchedanalysis. Eur J Obstet Gynecol Reprod Biol. 2016 Oct 29;207:115-120.8. Lee JK, Mahan M, Khan N, Hanna R, Elshaikh MA. Survival Outcomes inWomen With International Federation of Gynecology and Obstetrics StageIIIC2 Endometrial Carcinoma. Int J Radiat Oncol Biol Phys. 2016 Oct1;96(2S):E308.9. Tsafrir Z, Aoun J, Hanna R, Papalekas E, Schiff L, Theoharis E,Eisenstein D. Robotic Trachelectomy After Supracervical Hysterectomy forBenign Gynecologic Disease. JSLS. 2016 Jul-Sep;20(3).10. Xu Y, Burmeister C, Hanna RK, Munkarah A, Elshaikh MA. Predictors ofSurvival After Recurrence in Women With Early-Stage EndometrialCarcinoma. Int J Gynecol Cancer. 2016 Jul;26(6):1137-42.11. Xu Y, Hanna RK, Elshaikh MA. Adjuvant therapy of uterine clear cellcarcinoma: a review. Arch Gynecol Obstet. 2016 Mar;293(3):485-92.12. Elshaikh MA, Vance S, Kamal M, Burmeister C, Hanna RK, Rasool N,Siddiqui F. Influence of Comorbidity on the Risk of Death: A SingleInstitution Study of 1132 Women with Early-stage Uterine Cancer. Am JClin Oncol. 2017 Apr;40(2):183-188.13. Cattaneo R 2nd, Hanna RK, Jacobsen G, Elshaikh MA. Interval betweenhysterectomy and start of radiation treatment is predictive of recurrence inpatients with endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2014Mar 15;88(4):866-71.
Rabbie Kriakoss Hanna, MD 5Curriculum Vitae14. Haider M. Rahbar, Ramesh K. Kumar, Deepansh Dalela, Rabbie Hanna,Nilesh Gupta and Craig G. Rogers. Case report: Renal cell carcinoma withmetastasis to the myometrium. J Obst and Gynaecology Research. 2014Jun;40(6):1828-30.15. Hanna RK, Poniewierski MS, Laskey RA, Lopez MA, Shafer A, Van Le L,Crawford J, Dale DC, Gehrig PA, Secord AA, Havrilesky LJ, Lyman GH.Predictors of reduced relative dose intensity and its relationship tomortality in women receiving multi-agent chemotherapy for epithelialovarian cancer. Gynecol Oncol. 2013 Apr;129(1):74-80.16. Zaki M, Robbins J, Fatteh S, Mahan M, Hanna RK, Elshaikh MA.Histological Grade Predicts for Recurrence in Patients with UterineEndometrioid Carcinoma without Myometrial Involvement. AnticancerResearch 32: 4061-4065 (2012).17. Vance S, Yechieli R, Cogan C, Hanna R, Munkarah A, Elshaikh MA. Theprognostic significance of age in surgically staged patients with type IIendometrial carcinoma. Gynecol Oncol. 2012 Jul;126(1):16-9.18. Robin A Laskey, Marek S Poniewierski, Micael A Lopez, Rabbie KHanna, Angeles A Secord, Paola A Gehrig, Gary H Lyman. Predictors ofsevere and febrile neutropenia during primary chemotherapy for ovariancancer. Gynecol Oncol. 2012 Jun; 125(3):625-30.19. Hanna RK, Zhou C, Malloy KM, Gehrig PA, Bae-Jump VL. Metforminpotentiates the effects of paclitaxel in endometrial cancer cells throughinhibition of cell proliferation and modulation of the mTOR pathway.Gynecol Oncol. 2012 May; 125(2): 458-69.20. H Mahdi, R E Swensen, R Hanna, S Kumar, R Ali-Fehmi, A Semaan, HTamimi, R T Morris and A R Munkarah. Prognostic impact oflymphadenectomy in clinically early stage malignant germ cell tumour ofthe ovary. Br J Cancer. 2011 Aug 9;105(4):493-7.21. Haider Mahdi, Sanjeev Kumar, Rabbie Hanna, Adnan Munkarah, DavidLockhart, Robert Morris, Hisham Tamimi, Ron Swensen, and MarkDoherty. Disparities in treatment and survival between African Americanand White women with vaginal cancer. Gynecol Oncol. 2011Jul;122(1):3841.22. Mahdi H, Thrall M, Kumar S, Hanna R, Seward S, Lockhart D, Morris RT,Swensen R, and Munkarah AR. The prognostic impact of the ratio ofpositive lymph nodes on survival of epithelial ovarian cancer patients. JSurg Oncol. 2011 Jun 1;103(7):724-9.23. Rabbie K. Hanna and John T. Soper. The Role of Surgery and RadiationTherapy in the Management of Gestational Trophoblastic Disease.Oncologist 2010;15 593-600.24. Boggess JF, Gehrig PA, Cantrell L, Shafer A, Mendivil A, Rossi E, HannaR. Perioperative outcomes of robotically assisted hysterectomy for benigncases with complex pathology. Obstet Gynecol 2009;114: 585-93.
Rabbie Kriakoss Hanna, MD 6Curriculum VitaeBook chapters:1. Rabbie K. Hanna, MD and Adnan R. Munkarah, MD. Malignant Diseasein Pregnancies. In: High Risk Pregnancy, fifth edition. David James, PhilipJ. Steer, Carl P. Weiner, Bernard Gonik and Stephen C. Robson, editors.2017. Cambridge University Press.2. Rabbie K. Hanna, MD and John F. Boggess, MD. Robotic Surgery. In: AnAtlas of Gynecologic Oncology, Investigation, and Surgery, third edition. J.Richard Smith, Giuseppe Del Priore, Robert L. Coleman, and John M.Monaghan, editors. 2011. Informa Healthcare.3. Rabbie K. Hanna, MD and John F. Boggess, MD. Applications of SurgicalRobotics in Gynecologic Surgery. In: Surgical Robotics - SystemApplications and Visions. Jacob Rosen, Blake Hannaford, and Richard M.Satava, editors. 2011. Springer.4. Rabbie K. Hanna, MD, John T. Soper, MD and Chad Livasy, MD.Gestational Trophoblastic Disease. In: Gynecological CancerManagement. Daniel Clarke-Pearson and John Soper, editors. 2009.Wiley-Blackwell.5. Rabbie K. Hanna, MD, John T. Soper, MD and Chad Livasy, MD. OvarianTumors of Low Malignant Potential. In: Gynecological CancerManagement. Daniel Clarke-Pearson and John Soper, editors. 2009.Wiley-Blackwell.Abstracts:1. R. Rattana, T.E. Buekersa, V. Rajab, M. Hijazc, R.K. Hanna, S. Hamidb,S. Giria and A.R. Munkarah. Role of MCP-1 in promoting adiposity-drivenovarian cancer. Presented at the 50th Annual Meeting of the Society ofGynecologic Oncology March, 2019.2. R. Rattana, S. Sakrb, R. Ali-Fehmi, E. Abdulfatahb, R.K. Hanna, S. Giriaand A.R. Munkarah. S-nitrosoglutathione, a physiologic nitric oxide carrier,reduces immunosupression in ovarian cancer. Presented at the 49thAnnual Meeting of the Society of Gynecologic Oncology March, 2018.3. A.M. Tran, W. Yang, J.F. Boggess, L.D. Kowalski, J.M. Scalici, L.A.Cantrell, K.M. Schuler, A. Ivanova, R.K. Hanna and E.C. Rossi. BilateralSLN mapping for cervical cancer with ICG and robotic fluorescenceimaging is associated with greater accuracy in detecting metastaticdisease. Presented at the 47th Annual Meeting of the Society ofGynecologic Oncology March, 2016.4. Y. Xu, R.K. Hanna, C. Burmeister, A.R. Munkarah and M.A. Elshaikh.Predictors of survival after recurrence in women with early-stageendometrial carcinoma. Presented at the 47th Annual Meeting of theSociety of Gynecologic Oncology March, 2016.5. I. Mert, A.R. Munkarah, R.K. Hanna, J. Chhina, M.S. Carey, M. Llauradoand R. Rattan Is it time to repurpose metformin for the treatment of low-
Rabbie Kriakoss Hanna, MD 7Curriculum Vitaegrade ovarian cancer? Presented as a featured poster at the 47th AnnualMeeting of the Society of Gynecologic Oncology March, 2016.6. H.D. Hinshaw, J.F. Boggess, L.D. Kowalski, J.M. Scalici, L.A. Cantrell,K.M. Schuler, R.K. Hanna, A. Ivanova, D. Matei and E.C. Rossi. Therelationship between endometrial cancer sentinel lymph node micro andmacro metastases and uterine pathology features. Presented at the 47thAnnual Meeting of the Society of Gynecologic Oncology March, 2016.7. Z Tsafrir, J Aoun, E Papalekas, LD Schiff, E Theoharis, R Hanna, RSangha, D Eisenstein. Risk factors for Trachelectomy FollowingSupracervical Hysterectomy. Journal of Minimally Invasive Gynecology11/2015; 22(6):S82-S83.8. Tran AM, Yang W, Boggess JF, Kowalski LW, Scalici Jm, Cantrell LA,Schuler KM, Ivanova A, Hanna RK, Rossi EC. Bilateral SLN mapping forcervical cancer with ICG and robotic fluorescence imaging is associatedwith greater accuracy in detecting metastatic disease. Accepted for oralpresentation at the 47th SGO annual meeting (2016).9. Hinshaw H, Boggess JF, Kowalski LW, Scalici Jm, Cantrell LA, SchulerKM, Ivanova A, Hanna RK, Matei D, Rossi EC. The relationship betweenendometrial cancer sentinel lymph node micro and macro metastastasesand uterine pathology features. Accepted for poster presentation at the47th SGO annual meeting (2016).10. M. Hijaz, J. Chhina, S. Dar, C. Tebbe, Z. Al-Wahab, R.K. Hanna, R.Rattan, A.R. Munkarah. Synthetic lethality of PARP inhibitors andmetformin in BRCA1 intact ovarian cancer. Gynecol Oncol.137 (2015)S18.11. Emma C. Rossi, Rabbie K. Hanna, John F. Boggess. Sentinel lymphnode mapping for cervical cancer using Indocyanine green and the daVinci Si fluorescence imaging. Gynecol Oncol.125 (2012) S11.12. Rabbie K. Hanna. Robot assisted infra-gastric omentectomy. GynecolOncol.125 (2012) S40.13. Rabbie K. Hanna, Assad Semaan, Adnan Munkarah. Robot-assistedresection of localized para-aortic recurrence of uterine papillary serouscarcinoma at the level of the renal vessels: Approach and technique.Gynecol Oncol.125 (2012) S40.14. Sharon Hensley-Alford, A. Galka, Rabbie Hanna, Adnan Munkarah.Protective effect of bisphosonates on endometrial cancer incidence in thePLCO data. Gynecol Oncol.125 (2012) S161.15. S. Vance, R. Yechieli, C. Cogan, R. Hanna, A. Munkarah, M. Elshaikh.The Prognostic Significance Of Age In Surgically Staged Patients WithType II Endometrial Carcinoma. Gynecol Oncol.125 (2012) S147.16. Micael Lopez-Acevedo, Robin Laskey, Rabbie Hanna, Angeles AlvarezSecord, Marek Poniwierski, Paola Gehrig, Gary H Lyman, Laura J
Rabbie Kriakoss Hanna, MD 8Curriculum VitaeHavrilesky. Impact of platelet count in women with advanced ovariancancer receiving adjuvant multi-agent systemic chemotherapy. GynecolOncol.125 (2012) S68-69.17. Quinn Lippmann, Rabbie K. Hanna, John T Soper. Single-Agentmethotrexate for low-risk gestational trophoblastic disease. J Clin Oncol29: 2011 (suppl; abstr e15501).18. R. K. Hanna, W. K. Chiu, L. Van Le. Endometrial cancer and the elderly:The impact of age on disease and outcome. J Clin Oncol 29: 2011 (suppl;abstr e19731).19. L. J. Havrilesky, R. K. Hanna, M. S. Poniewierski, R. Laskey, A. A.Secord, P. A. Gehrig, M. A. Lopez, A. Shafer, L. Van Le, D. C. Dale, J.Crawford, G. H. Lyman. Relationship between relative dose intensity andmortality in women receiving combination chemotherapy for stage III-IVepithelial ovarian cancer. J Clin Oncol 29: 2011 (suppl; abstr 5084).20. Rabbie Hanna, Marek Poniwierski, Robin Laskey, Micael Lopez, AngelesAlvarez Secord, Laura J. Havrilesky, and Gary H. Lyman. Predictors andEffects of Reduced Relative Dose Intensity in Women Receiving PrimaryCourse of Chemotherapy for Ovarian Cancer. Gynecol Oncol.120 (2011)S98.21. H Mahdi, R Hanna, S Seward, R Swensen, H Tamimi, R Morris, AMunkarah. Prognostic impact of lymphadenectomy in clinically early stageovarian malignant germ cell tumor (OGCT). Gynecol Oncol.120 (2011)S85.22. Robin Laskey, Marek Poniewierski, Micael Lopez, Rabbie Hanna,Angeles Alvarez Secord, Paola Gehrig, Gary Lyman, Laura Havrilesky.Predictors of Severe and Febrile Neutropenia During PrimaryChemotherapy for Ovarian Cancer. Gynecol Oncol.120 (2011) S74.23. H. Mahdi, S. Kumar, A. Munkarah, R. Hanna, D. Lockhart, H. Tamimi, R.Swensen, and M. Doherty. Disparities in treatment and survival betweenAfrican-American and white women with vaginal cancer. GynecolOncol.120 (2011) S117.24. Rabbie K. Hanna and John F. Boggess. Robotic Assisted Ileal CutaneousUrinary Diversion. Gynecol Oncol. 116 (2010) S12.25. Rabbie K. Hanna and John F. Boggess. Robotic assisted radicaltrachelectomy with uterine artery preservation. Gynecol Oncol. 116 (2010)S167.26. Rabbie K. Hanna and John F. Boggess. Robotic assisted comprehensivepelvic lymph node dissection, a systematic approach. Gynecol Oncol. 116(2010) S168.27. Hanna RK, Malloy KM, Zhou C, Brante Sampey, Gehrig, PA and BaeJump VL. Genistein and soy inhibit proliferation of endometrial cancercells by G2 cell cycle arrest and activation of the MAPK pathway. GynecolOncol. 116 (2010) S154.
Rabbie Kriakoss Hanna, MD 9Curriculum Vitae28. Hanna RK, Zhou C, Malloy KM, Gehrig, PA, Kaufman DG and Bae-JumpVL. Metformin potentiates the effects of paclitaxel in endometrial cancercells through inhibition of cell proliferation and modulation of the mTORpathway. Gynecol Oncol. 116 (2010) S160.29. Rabbie K. Hanna MD, Leigh A. Cantrell MD, Alberto Mendivil, MD, PaolaA. Gehrig MD, John F. Boggess MD. A cost analysis of robotic ascompared to conventional laparoscopy for endometrial cancer staging.Gynecol Oncol. 112 (2009) S166.30. Rabbie K Hanna, Aaron Shafer, Linda Van Le. Capping the dose ofpaclitaxel in endometrial cancer patients: Does this affect clinicaloutcome? J Clin Oncol 27, 2009 (suppl; abstr e16563).31. Schimp VL, Solomon LA, Hanna R, Bryant CS, Deppe G, Munkarah AR.Charlson-age comorbidity index as predictor of outcome in patients withepithelial ovarian cancer. Gynecol Oncol. 101 (2006) S115-116.32. Schimp VL, Bryant CS, Solomon LA, Hanna R, Ali-Fehmi R, Morris RT,Munkarah AR. Impact of ethnicity on survival among African Americanpatients with epithelial ovarian cancer. Gynecol Oncol. 101 (2006) S141142.Surgical Video Presentations:1. Rabbie K. Hanna, Miriana Hijaz, Robotic resection of localized persistentovarian cancer in the aortocaval region. Presented at the 46th AnnualMeeting of the Society of Gynecologic Oncology -March/2015.2. Rabbie K. Hanna. Inferior Mesenteric Artery Avulsion and Repair duringRobot-assisted Laparoscopic Staging for Endometrial Cancer. Presentedat the 45th Annual Meeting of the Society of Gynecologic Oncology March/2014.3. Matthew Palmer, Randa J. Jalloul and Rabbie K. Hanna. RoboticAssisted Dissection of the Uterine Artery at Its Origin: Approach andTechnique. Presented at the 2012 Joint Annual Meeting for Society ofLaparoendoscopic Surgeons (SLS) - Minimally Invasive RoboticAssociation (MIRA) - Society of Robotic Surgery (SRS).4. Rabbie K. Hanna, Assad Semaan and Adnan R. Munkarah. Robotassisted resection of localized para-aortic recurrence of uterine papillaryserous carcinoma at the level of the renal vessels: Approach andTechnique. Presented at the 43rd Annual Meeting of the Society ofGynecologic Oncology -March/2012.5. Rabbie K. Hanna. Robot assisted infragastric omentectomy. Presented ata. The 43rd Annual Meeting of the Society of Gynecologic OncologyMarch/2012.b. The Surgical Film Festival, Detroit Michigan October/2011.
Rabbie Kriakoss Hanna, MD 10Curriculum Vitae6. Randa Jalloul and Rabbie K. Hanna. Robot assisted dissection of theuterine artery at its origin, approach and technique. Presented at theSurgical Film Festival, Detroit Michigan Mar/2012.7. Rabbie K. Hanna and John F. Boggess. Robotic Assisted Pelvic LymphNode Dissection During Pregnancy for Cervical Cancer. Presented at theFourth International Gynecologic Oncology Robotic Symposium (IGORSIV)-May/2011.8. John Boggess and Rabbie K. Hanna. Robotic radical trachelectomy. Aninvited surgical video presented at the 42st Annual Meeting of the Societyof Gynecologic Oncology-March/2011 Film Festival.9. Rabbie K. Hanna and John F. Boggess. Robotic Assisted Ureteroneocystotomy. A surgical video presented at:a. The Fourth International Gynecologic Oncology RoboticSymposium (IGORS IV) and Third World Robotic GynecologicCongress (WRGS III) meetings-May/2011.b. The 2010 Mid-Atlantic Gynecologic Oncology Society annualmeeting Oct/2010.10. Rabbie K. Hanna and John F. Boggess. Robotic Assisted Para-AorticLymph Node Dissection (PA-LND), preparation and technique. A surgicalvideo presented at:a. The Fourth International Gynecologic Oncology RoboticSymposium (IGORS IV)-May/2011 by John Boggess MD during aninteractive surgical tutorial-based session on “Optimizing RoboticApproaches to Lymphadenectomy-Para-Aortic Lymphadenectomy”.b. The Third International Gynecologic Oncology Robotic Symposium(IGORS III)-April/2010.c. The 2010 Mid-Atlantic Gynecologic Oncology Society annualmeeting Oct/2010.11. Rabbie K. Hanna and John F. Boggess. Robotic Approach to BilateralSalpingo-Oophorectomy with Significant Adhesions. A surgical videopresented at:a. The Third International Gynecologic Oncology Robotic Symposium(IGORS III)-April/2010b. The Second World Robotic Gynecologic Congress (WRGCII)/2010-April/2010.12. Rabbie K. Hanna and John F. Boggess. Robotic Assisted Debulking ofEnlarged Pelvic Lymph Nodes Utilizing Anatomic Planes. A surgical videopresented at the Third International Gynecologic Oncology RoboticSymposium (IGORS III)-April/2010.13. Rabbie K. Hanna and John F. Boggess. Robotic assisted comprehensivepelvic lymph node dissection, a systematic approach. A surgical videopresented at the 411st Annual Meeting of the Society of GynecologicOncology-March/2010 Film Festival.
Rabbie Kriakoss Hanna, MD 11Curriculum Vitae14. Rabbie K. Hanna and John F. Boggess. Robotic assisted radicaltrachelectomy with uterine artery preservation. A surgical video presentedat the 41st Annual Meeting of the Society of Gynecologic Oncology March/2010 Film Festival.15. Rabbie K. Hanna and John F. Boggess. Robotic Assisted Ileal CutaneousUrinary Diversion. A surgical video presented as a focused plenarypresentation at:a. The 41st Annual Meeting of the Society of Gynecologic Oncology March/2010b. The Third International Gynecologic Oncology Robotic Symposium(IGORS III)-March/2010.16. Rabbie K. Hanna and John F. Boggess. Robotic Assisted Pelvic LymphNode Dissection, A Systematic Approach. Presented at the 2009 MidAtlantic Gynecologic Oncology Society Annual Meeting.17. Rabbie K. Hanna and John F. Boggess. Radical Trachelectomy withUterine Artery Preservation. Presented at the 2009 Mid-AtlanticGynecologic Oncology Society Annual Meeting-Oct/2009.18. Rabbie K. Hanna and John F. Boggess. Robotic Assisted RadicalHysterectomy. Presented at the 2009 Mid-Atlantic Gynecologic OncologySociety Annual Meeting-Oct/2009.Oral Presentations:1. A.M. Tran, W. Yang, J.F. Boggess, L.D. Kowalski, J.M. Scalici, L.A.Cantrell, K.M. Schuler, A. Ivanova, R.K. Hanna and E.C. Rossi. BilateralSLN mapping for cervical cancer with ICG and robotic fluorescenceimaging is associated with greater accuracy in detecting metastaticdisease. Presented at the 47th Annual Meeting of the Society ofGynecologic Oncology March, 2016.2. M. Hijaz, J. Chhina, S. Dar, C. Tebbe, Z. Al-Wahab, R.K. Hanna, R.Rattan, A.R. Munkarah. Synthetic lethality of PARP inhibitors andmetformin in BRCA1 intact ovarian cancer. Presented as a focusedplenary at the 46th Annual Meeting of the Society of Gynecologic OncologyMarch, 2015.3. Ali Hassan Hamed, Timothy E. Stump, Rabbie K. Hanna, Emma C.Rossi. Perioperative outcomes following mini-laparotomy to extract largemalignant uteri during robotic surgery. Presented at the 43rd AAGL GlobalCongress of Minimally Invasive Gynecology, Nov 2014, Vancouver, BritishColumbia, Canada.4. Randa J Jalloul and Rabbie K Hanna. Is body mass index a prognosticfactor in surgically staged patients with type II endometrial carcinoma.Presented at the Michigan Section, American College of Obstetricians andGynecologists Junior Fellow Research Day, Lansing, Michigan May 2012.
Rabbie Kriakoss Hanna, MD 12Curriculum Vitae5. Emma C. Rossi, Rabbie K. Hanna and John F. Boggess. Sentinel LymphNode Mapping for Cervical Cancer Using Indocyanine Green and the daVinci Si Fluorescence imaging. Presented at the 43rd Annual Meeting ofthe Society of Gynecologic Oncology-March/2012.6. Quinn Lippmann, Rabbie K. Hanna, John T Soper. Multimodal TreatmentApproach to Gestational Trophoblastic Neoplasia. Presented at the 2011Mid-Atlantic Gynecologic Oncology Society annual meeting.7. Rabbie Hanna, Marek Poniwierski, Robin Laskey, Micael Lopez, AngelesAlvarez Secord, Laura J. Havrilesky, Gary H. Lyman. Predictors andeffects of reduced relative dose intensity in women receiving primarycourse of chemotherapy for ovarian cancer. Presented as an oral plenaryin the Fellows and Resident Plenary Session at the 42nd Annual Meetingof the Society of Gynecologic Oncology-March/2011.8. Hanna RK, Zhou C, Malloy KM, Gehrig, PA, Kaufman DG and Bae-JumpVL. Metformin potentiates the effects of paclitaxel in endometrial cancercells through inhibition of cell proliferation and modulation of the mTORpathway. Presented at: The Seventh University Research Day at theUniversity of North Carolina at Chapel Hill, March 2011.9. Rabbie K. Hanna and John F. Boggess. Robotic Assisted Ileal CutaneousUrinary Diversion. A surgical video presented as a focused plenarypresentation at the 41st Annual Meeting of the Society of GynecologicOncology/2010.10. Rabbie K. Hanna, Leigh A. Cantrell, Paola A. Gehrig, Alberto Mendivil,John F. Boggess. Robotic versus conventional laparoscopy forendometrial cancer staging, is it cost-effective? Presented at the Societyof Pelvic Surgeons 2009.11. Hanna RK, Malloy KM, Zhou C, Gehrig, PA and Bae-Jump VL. Genisteinand soy extract inhibit proliferation of endometrial cancer cells by G2 cellcycle arrest. Presented at the 2009 Mid-Atlantic Gynecologic OncologySociety annual meeting.12. Rossi EC, Hanna RK, Harris J, Boggess JF. Factors associated with thedevelopment of lymphedema after robotically assisted endometrialstaging. Presented at the 2009 Mid-Atlantic Gynecologic Oncology Societyannual meeting.13. Rabbie K. Hanna, Leigh A. Cantrell, Alberto Mendivil, Paola A. Gehrig,John F. Boggess. A cost analysis of robotic as compared to conventionallaparoscopy for endometrial cancer staging. Presented at the secondannual (International Gynecologic Oncology Robotic Symposium) IGORSconference 2008.Poster Presentations:1. R. Rattana, T.E. Buekersa, V. Rajab, M. Hijazc, R.K. Hanna, S. Hamidb,S. Giria and A.R. Munkarah. Role of MCP-1 in promoting adiposity-driven
Rabbie Kriakoss Hanna, MD 13Curriculum Vitaeovarian cancer. Presented at the 50th Annual Meeting of the Society ofGynecologic Oncology March, 2019.2. R. Rattana, S. Sakrb, R. Ali-Fehmi, E. Abdulfatahb, R.K. Hanna, S. Giriaand A.R. Munkarah. S-nitrosoglutathione, a physiologic nitric oxide carrier,reduces immunosupression in ovarian cancer. Presented at the 49thAnnual Meeting of the Society of Gynecologic Oncology March, 2018.3. H.D. Hinshaw, J.F. Boggess, L.D. Kowalski, J.M. Scalici, L.A. Cantrell,K.M. Schuler, R.K. Hanna, A. Ivanova, D. Matei and E.C. Rossi. Therelationship between endometrial cancer sentinel lymph node micro andmacro metastases and uterine pathology features. Presented as afeatured poster at the 47th Annual Meeting of the Society of GynecologicOncology March, 2016.4. Y. Xu, R.K.
3. July 2011- Aug 2020: Gynecologic Oncology Senior Staff Division of Gynecologic Oncology Department of Women's Health Henry Ford Health System Detroit, Michigan. 4. Aug 2014- Jun 2017: Gynecologic Oncology Attending Hurley Medical Center-Flint/Michigan. Board Certifications and Licensure: 1. Gynecologic Oncology/Board Certified April, 9th .
